Jefferies Group LLC Alaunos Therapeutics, Inc. Transaction History

Jefferies Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.41 - $1.24 $29,757 - $89,999	72,580 New	72,580 $39,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $142,929 - $269,721	-230,531 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $251,278 - $435,703	230,531 New	230,531 $89,000
Q1 2020 May 15, 2020	SELL	$1.9 - $4.98 $37,124 - $97,304	-19,539 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$3.95 - $5.35 $77,179 - $104,533	19,539 New	19,539 $92,000
Q1 2019 May 15, 2019	SELL	$2.0 - $4.4 $231,222 - $508,688	-115,611 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.61 - $3.62 $30,008 - $67,473	18,639 Added 19.22%	115,611 $216,000
Q3 2018 Nov 14, 2018	BUY	$2.26 - $3.27 $110,028 - $159,199	48,685 Added 100.82%	96,972 $310,000
Q2 2018 Aug 14, 2018	BUY	$3.02 - $4.94 $145,826 - $238,537	48,287 New	48,287 $146,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.